Abnormal patterns of microtubule-associated protein-2 (MAP-2) immunolabeling in neuronal nuclei and Lewy bodies in Parkinson's disease substantia nigra brain tissues

被引:43
作者
D'Andrea, MR [1 ]
Ilyin, S [1 ]
Plata-Salaman, CR [1 ]
机构
[1] RW Johnson Pharmaceut Res Inst, Spring House, PA 19477 USA
关键词
alpha-synuclein; immunohistochemistry; immunofluorescence; Lewy bodies; microtubule-associated protein-2; Parkinson's disease; substantia nigra; ubiquitin;
D O I
10.1016/S0304-3940(01)01811-0
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Parkinson's disease (PD) is a neurodegenerative disorder associated with the appearance of cytoplasmic Lewy bodies (LBs) in dopaminergic neurons of the substantia nigra and the progressive loss of these neurons. Cytoskeleton alterations and associated impairments of neuronal transport may contribute to neuronal death. Microtubule-associated protein-2 (MAP-2), a cytoskeleton protein is localized primarily in neuronal dendrites and is known to stabilize microtubule assembly and mediate their interactions with other neuronal cell components. To determine if alterations in MAP-2 morphology are present in PD neurons, we used single and double immunohistochemical and immunofluorescent techniques to characterize MAP-2 in PD neuronal tissues. We report abnormal MAP-2 immunolabeling in some neurons of the substantia nigra of PD brain tissues, which were not observed in the normal, age-matched, control brain tissues. Furthermore, MAP-2 was co-localized with alpha -synuclein and ubiquitin in cytoplasmic LBs of neurons. Surprisingly, MAP-2 was also found to form fibrous aggregates and crystal-like structures within neuronal nuclei. These PD-associated alterations in MAP-2 morphology and distribution suggest that impaired neuronal transport may contribute to the progression of neuronal loss in the brains of PD patients. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:137 / 140
页数:4
相关论文
共 14 条
[1]  
[Anonymous], 1987, BASIC PATHOLOGY
[2]   Application of triple immunohistochemistry to characterize amyloid plaque-associated inflammation in brains with Alzheimer's disease [J].
D'Andrea, MR ;
Reiser, PA ;
Gumula, NA ;
Hertzog, BM ;
Andrade-Gordon, P .
BIOTECHNIC & HISTOCHEMISTRY, 2001, 76 (02) :97-106
[3]   Localization of protease-activated receptors-1 and-2 in human mast cells: Indications for an amplified mast cell degranulation cascade [J].
D'Andrea, MR ;
Rogahn, CJ ;
Andrade-Gordon, P .
BIOTECHNIC & HISTOCHEMISTRY, 2000, 75 (02) :85-90
[4]  
Daniel S E, 1993, J Neural Transm Suppl, V39, P165
[5]   TOWARD A DEFINITION OF PARKINSONS-DISEASE [J].
DUVOISIN, RC ;
GOLBE, LI .
NEUROLOGY, 1989, 39 (05) :746-746
[6]  
Giasson BI, 2000, J NEUROSCI RES, V59, P528, DOI 10.1002/(SICI)1097-4547(20000215)59:4<528::AID-JNR8>3.0.CO
[7]  
2-0
[8]   THE SIGNIFICANCE OF THE LEWY BODY IN THE DIAGNOSIS OF IDIOPATHIC PARKINSONS-DISEASE [J].
GIBB, WRG ;
LEES, AJ .
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 1989, 15 (01) :27-44
[9]   Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease [J].
Hurtig, HI ;
Trojanowski, JQ ;
Galvin, J ;
Ewbank, D ;
Schmidt, ML ;
Lee, VMY ;
Clark, CM ;
Glosser, G ;
Stern, MB ;
Gollomp, SM ;
Arnold, SE .
NEUROLOGY, 2000, 54 (10) :1916-1921
[10]   Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain α-synuclein immunoreactivity [J].
Irizarry, MC ;
Growdon, W ;
Gomez-Isla, T ;
Newell, K ;
George, JM ;
Clayton, DF ;
Hyman, BT .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1998, 57 (04) :334-337